Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

Toxicities and Treatment Selection of Endocrine-Based Therapies in HR+/HER2– Breast Cancer

Panelists discuss how genotype-directed treatment options compare with fulvestrant, factors influencing the choice of therapy, and strategies for managing adverse events with this class of therapies.

Video content above is prompted by the following:

Dr. Bardia to All Panelists: How do these options compare? Why might you choose one of these options vs fulvestrant?

What are your strategies for AE adverse event management with this class of therapies?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Tanya Gupta, MD
March 21st 2025

Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.
March 15th 2025

The OncFive: Top Oncology Articles for the Week of 3/9

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Vepdegestrant in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 11th 2025

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer